Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 4:30 AM ET


Company Overview of Horizon Pharma plc

Company Overview

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pa...

Connaught House

1st Floor

1 Burlington Road

Dublin,  4


Founded in 2005

692 Employees


353 1 772 2100

Key Executives for Horizon Pharma plc

Chairman, Chief Executive Officer and President
Age: 48
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice President of Finance
Age: 50
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice President
Age: 56
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 60
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice President
Age: 47
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.

Horizon Pharma plc Key Developments

The U.S. Patent And Trademark Office Issues Additional Notice Of Allowance With Claims Covering PENNSAID(r)

Horizon Pharma plc announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/705,606 (U.S. publication number 2015-0231262), entitled 'Diclofenac Topical Formulation' that covers Horizon's U.S. approved product PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire October 17, 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Horizon Pharma plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 05:15 PM

Horizon Pharma plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 05:15 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Timothy P. Walbert, Chairman, Chief Executive Officer and President.

Horizon Pharma plc Names George Hampton as Executive Vice President, Global Orphan Business Unit and International Operations

Horizon Pharma plc named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee. Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015. Most recently, Hampton served as president and chief executive officer of a privately held technology company.

Similar Private Companies By Industry

Company Name Region
BioClin Research Laboratories Ltd. Europe
AbbVie Ireland Limited Europe
Abbott Mature Products Management Limited Europe
Rottapharm LTD. Europe
Dignity Sciences Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Horizon Pharma plc, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at